Links between oral and gastrointestinal health

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 1, 2010, Pages 31-35

  Logan, Richard M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Division of Surgical Pathology   (Australia)

Author keywords

Gastro oesophageal reflux disease; Gastrointestinal health; Inflammatory bowel disease; Mucositis; Oral health

Indexed keywords

ENTERITIS; HUMAN; MOUTH; MOUTH DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TOOTH DISEASE;

HUMANS; INFLAMMATORY BOWEL DISEASES; MOUTH; MOUTH DISEASES; TOOTH EROSION;

EID: 77950354836     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833575e4     Document Type: Article

References (31)

1. Ali DA, Brown RS, Rodriguez LO, et al. Dental erosion caused by silent gastroesophageal reflux disease. J Am Dent Assoc 2002; 133:734-737.
2. Liberali SAC. Oral impact of gastro-oesophageal reflux disease: a case report. Aust Dent J 2008; 53:176-179.
3. Barron R, Carmichael R, Marcon M, et al. Dental erosion in gastroesophageal reflux disease. J Can Dent Assoc 2003; 69:84-89.
4. Regezi J, Sciubba J, Jordan R. Oral pathology: clinical pathologic correlations. 5th ed. Philadelphia: Saunders, Elsevier; 2008.
5. Holbrook WP, Furuholm J, Gudmundsson K, et al. Gastric reflux is a significant causative factor of tooth erosion. J Dent Res 2009; 88:422-426.
6. Belhocine K, Galmiche J-P. Epidemiology of the complications of gastroesophageal reflux disease. Dig Dis 2009; 27:7-13.
7. Katz J, Shenkman A, Stavropoulos F, et al. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis 2003; 9:34-40.
8. Daley T, Armstrong J. Oral manifestations of gastrointestinal diseases. Can J Gastroenterol 2007; 21:241-244.
9. Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008; 40:S253-S259.
10. Jose F, Garnett E, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:63-68.
11. Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008; 103:2092-2098.
12. Yü ksel I, Basar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:546-550.
13. Tilakaratne W, Freysdottir J, Fortune F. Orofacial granulomatosis: a review on aetiology and pathogenesis. J Oral Pathol Med 2008; 37:191-195.
14. Ayangco L, Rogers R, Sheridan P. Pyostomatitis vegetans as an early sign of reactivation of Crohn's disease: a case report. J Periodontol 2002; 73:1512-1516.
15. Rikardsson S, Jonsson J, Hultin M, et al. Perceived oral health in patients with Crohn's disease. Oral Health Prev Dent 2009; 7:277-282.
16. Yasuda M, Amano H, Nagai Y, et al. Pyodermatitis-pyostomatitis vegetans associated with ulcerative colitis: successful treatment with total colectomy and topical tacrolimus. Dermatology 2008; 217:146-148.
17. Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:e1-e10.
18. Logan R. Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol 2009; 45:844-848.
19. Aprile G, Ramoni M, Keefe D, et al. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2008; 112:284-292.
20. Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8:33-39.
21. Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33:448-460.
22. Blijlevens NMA, Logan RM, Netea MG. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother 2009; 63:i36-i40.
23. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007; 19:323-327.
24. Sonis S. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009; 45:1015-1020.
25. Logan R, Stringer A, Bowen J, et al. Is the pathobiology of chemotherapyinduced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63:239-251.
26. Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41.
27. Keefe D, Schubert M, Elting L, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820-831.
28. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18:817-826.
29. Lee BD, Lee W, Oh SH, et al. A case report of Gardner syndrome with hereditary widespread osteomatous jaw lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2009; 107:e68-e72.
30. Santos P, Neto C, Machado S, et al. Perioral pigmentation: what is your diagnosis? Dermatol Online J 2008; 14:16.
31. Pontes H, Neto N, Ferreira K, et al. Oral manifestations of vitamin B12 deficiency: a case report. J Can Dent Assoc 2009; 75:533-537.